Literature DB >> 25823783

SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy.

Chun-Lai Ma1, Xun-Yi Wu, Zheng Jiao, Zhen Hong, Zhi-Yuan Wu, Ming-Kang Zhong.   

Abstract

AIM: Associations between the effects of SCN1A, SCN2A, ABCC2 and UGT2B7 genetic polymorphisms and oxcarbazepine (OXC) maintenance doses in Han Chinese epileptic patients were investigated. PATIENTS &
METHODS: Genetic polymorphisms were detected in 184 epileptic patients receiving OXC monotherapy by high-resolution melting curve and TaqMan method.
RESULTS: Carriers of the SCN1A IVS5-91G>A, UGT2B7 c.802T>C and ABCC2 c.1249G>A variant alleles required significantly higher OXC maintenance doses than noncarriers (p < 0.05). Corresponding relative ln (concentration-dose ratios) values for SCN1A IVS5-91 variants differed by the genotypic order GG > GA > AA.
CONCLUSION: SCN1A, UGT2B7 and ABCC2 genetic polymorphisms are associated with OXC maintenance doses and may be useful for the personalization of OXC therapy in epileptic patients. Further studies are needed. Original submitted 6 June 2014; Revision submitted 5 September 2014.

Entities:  

Keywords:  ABCC2; SCN1A; SCN2A; UGT2B7; epilepsy; genetic polymorphisms; oxcarbazepine

Mesh:

Substances:

Year:  2015        PMID: 25823783     DOI: 10.2217/pgs.14.186

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  12 in total

Review 1.  Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.

Authors:  Ramon Cacabelos
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

2.  Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.

Authors:  Yao Lu; Youxin Fang; Xunyi Wu; Chunlai Ma; Yue Wang; Lan Xu
Journal:  Eur J Clin Pharmacol       Date:  2016-11-29       Impact factor: 2.953

3.  Analysis of influencing factors on monohydroxylated derivative of oxcarbazepine plasma concentration in children with epilepsy.

Authors:  Nannan Yao; Shan Huang; Aiwen Huang; Hongtao Song
Journal:  Eur J Clin Pharmacol       Date:  2022-08-25       Impact factor: 3.064

4.  Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.

Authors:  Wei-Wei Lin; Xi-Wen Li; Zheng Jiao; Jin Zhang; Xin Rao; Da-Yong Zeng; Xin-Hua Lin; Chang-Lian Wang
Journal:  Eur J Clin Pharmacol       Date:  2018-11-19       Impact factor: 2.953

5.  Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.

Authors:  Cara Chang; Yichun Hu; Susan L Hogan; Nickie Mercke; Madeleine Gomez; Cindy O'Bryant; Daniel W Bowles; Blessy George; Xia Wen; Lauren M Aleksunes; Melanie S Joy
Journal:  Int J Mol Sci       Date:  2017-06-22       Impact factor: 5.923

Review 6.  Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis.

Authors:  Malek Chouchi; Wajih Kaabachi; Hedia Klaa; Kalthoum Tizaoui; Ilhem Ben-Youssef Turki; Lamia Hila
Journal:  BMC Neurol       Date:  2017-02-15       Impact factor: 2.474

Review 7.  Pharmacogenomics in epilepsy.

Authors:  Simona Balestrini; Sanjay M Sisodiya
Journal:  Neurosci Lett       Date:  2017-01-10       Impact factor: 3.046

8.  Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.

Authors:  Xue Yang; Yuanliang Yan; Shu Fang; Shuangshuang Zeng; Hongying Ma; Long Qian; Xi Chen; Jie Wei; Zhicheng Gong; Zhijie Xu
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

9.  The influence of concomitant antiepileptic drugs on lamotrigine serum concentrations in Northwest Chinese Han population with epilepsy.

Authors:  Xiaonian Han; Jing Huang; Jianhua Lv; Li Ma; Lirong Peng; Jinping Wang; Xiaojing Nie; Li Xia; Xin Zan
Journal:  PLoS One       Date:  2019-01-15       Impact factor: 3.240

10.  Association of SCN1A, SCN2A, and UGT2B7 Polymorphisms with Responsiveness to Valproic Acid in the Treatment of Epilepsy.

Authors:  Yuan Lu; Quanping Su; Ming Li; Alimu Dayimu; Xiaoyu Dai; Zhiheng Wang; Fengyuan Che; Fuzhong Xue
Journal:  Biomed Res Int       Date:  2020-02-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.